Investor pressure on Pfizer to downsize radically has been rising for several months, controversial as it is, but Sanford Bernstein analyst...

Angus Russell is CEO of Shire PLC . Shire is a global specialty biopharmaceutical company with 4300 employees in 28 countries. He will be th...

… FedFinancial Federal Credit Union, serving federal employees and their families in the Washington and Baltimore areas since 1935. OK, so ...

It was quiet on the deal making front as major news this week was of a regulatory or clinical nature. Despite a three-month delay, GlaxoSmit...

First, there were just words. Then there was a maiden dividend , the first of regular payouts to shareholders . Now there's a white pape...

The biggest deal of the week, Daiichi’s purchase of the California biotech Plexxikon for $805 million upfront, prompted headlines elsewhere ...

Shire's made some brilliant calls over the years. Buying genetic-diseases-focused Transkaryotic Therapies in 2005 for $ 1.57 billion was...

Welcome to the jury service edition. We were called in to do our civic duty this week, and we were stunned when we made it through the voir ...

The first two new therapies cleared by FDA in 2011 feel like hail from a bygone era: a serotonin inhibitor antidepressant and an angiotensin...

For the start-up community --and increasingly certain distressed VCs -- the birth of a new fund devoted to early stage biopharma investing i...